In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Divesting Horlicks Nutritional Business, Investing In OTC Production

This article is powered by The Rose Sheet

Executive Summary

Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.

Advertisement

Related Content

Horlicks Brings Unilever 'Transformative' Nutritional Deal, Market Challenges
Health Warrior To PepsiCo: Latest Healthy Pivot Among Food And Beverage Giants
GSK’s Horlicks Review Plan - Some Early Expectations In India
Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS121843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel